{
    "report_title": "Industry Report on Insulin Manufacturing",
    "report_date": "2023",
    "key_statistics": {
        "revenue": {
            "revenue_dollars": 2635000000,
            "revenue_cagr_historical": {
                "begin_year": 2005,
                "end_year": 2023,
                "revenue_cagr_value": 2.76
            },
            "revenue_cagr_projected": {
                "begin_year": 2023,
                "end_year": 2029,
                "revenue_cagr_value": 1.79
            }
        },
        "profit": {
            "profit_dollars": 941000000,
            "profit_cagr_historical": {
                "begin_year": 2005,
                "end_year": 2023,
                "profit_cagr_value": 4.2
            },
            "profit_cagr_projected": {
                "begin_year": 2023,
                "end_year": 2029,
                "profit_cagr_value": 3.5
            }
        },
        "profit_margins": {
            "profit_margins_percentage": 35.7,
            "profit_margins_cagr_historical": {
                "begin_year": 2005,
                "end_year": 2023,
                "profit_margins_cagr_value": 1.4
            },
            "profit_margins_cagr_projected": {
                "begin_year": 2023,
                "end_year": 2029,
                "profit_margins_cagr_value": 1.2
            }
        },
        "industry_value_added": {
            "industry_value_added_dollars": 1311000000,
            "industry_value_added_cagr_historical": {
                "begin_year": 2005,
                "end_year": 2023,
                "industry_value_added_cagr_value": 3.5
            },
            "industry_value_added_cagr_projected": {
                "begin_year": 2023,
                "end_year": 2029,
                "industry_value_added_cagr_value": 1.3
            }
        },
        "employees": {
            "employees_count": 2850,
            "employees_cagr_historical": {
                "begin_year": 2005,
                "end_year": 2023,
                "employees_cagr_value": 1.5
            },
            "employees_cagr_projected": {
                "begin_year": 2023,
                "end_year": 2029,
                "employees_cagr_value": 1.2
            }
        },
        "wages": {
            "wages_dollars": 304000000,
            "wages_cagr_historical": {
                "begin_year": 2005,
                "end_year": 2023,
                "wages_cagr_value": 3.0
            },
            "wages_cagr_projected": {
                "begin_year": 2023,
                "end_year": 2029,
                "wages_cagr_value": 2.5
            }
        },
        "imports": {
            "imports_dollars": 1254000000,
            "imports_cagr_historical": {
                "begin_year": 2005,
                "end_year": 2023,
                "imports_cagr_value": 2.5
            },
            "imports_cagr_projected": {
                "begin_year": 2023,
                "end_year": 2029,
                "imports_cagr_value": 2.0
            }
        },
        "exports": {
            "exports_dollars": 536000000,
            "exports_cagr_historical": {
                "begin_year": 2005,
                "end_year": 2023,
                "exports_cagr_value": 2.5
            },
            "exports_cagr_projected": {
                "begin_year": 2023,
                "end_year": 2029,
                "exports_cagr_value": 1.8
            }
        }
    },
    "executive_summary": "Companies in this industry produce insulin, a treatment for diabetes, which is one of the top health concerns for the US population. In 2020, 11.3% of the US population, equivalent to 37.3 million people, were diagnosed with diabetes, according to the CDC. Thanks to medical advancements, insulin has become more widely accessible to a larger share of the diabetic population over the past years. But industry revenue is expected to fall at a CAGR of 5.9% to $2.6 billion over the five years to 2023, including an expected 3.5% growth in 2023 alone.",
    "current_performance": [
        {
            "current_performance_point_title": "Insulins are essential for treating diabetes",
            "current_performance_point_description": "Diabetes is a chronic ailment in which the body doesn't produce enough insulin to assist blood sugar entering the body's cells. As a result, this results in excessive blood glucose staying in the body, causing high glucose levels. There are two main types of diabetes: type I and type II. While type II can be prevented by adjusting lifestyle and diet, type I diabetes is unpreventable as the body fails to produce insulin."
        }
    ],
    "future_outlook": [
        {
            "future_outlook_point_title": "Insulin Prices Will Continue Falling",
            "future_outlook_point_description": "The big three have announced the biggest price cuts of the decade, reducing some of their most prescribed insulin prices by over 70.0%. Since the Inflation Reduction Act of 2022 caps a monthly supply of insulin at $35.00 for Medicare Part D patients, Eli Lilly has taken a similar approach."
        },
        {
            "future_outlook_point_title": "Technology Provides Room for Growth",
            "future_outlook_point_description": "Automated insulin delivery (AID) system has been continuously improved. AID systems use Hybrid Closed-Loop or Artificial Pancreas technology, which helps to constantly alter insulin injection doses according to the body's blood level."
        },
        {
            "future_outlook_point_title": "External Competition Will Rise",
            "future_outlook_point_description": "While insulin treatment is considered unsubstitutable in treating diabetes, artificial pancreatic islet cells can be implanted into the patient's body."
        }
    ],
    "industry_definition": "Companies in this industry develop and produce hormones that lower the level of blood glucose. These products are typically used to treat type 1 and type 2 diabetes mellitus.",
    "industry_impact": {
        "positive_impact_factors": [
            "Barriers To Entry Level high - steady"
        ],
        "negative_impact_factors": [
            "Life Cycle Stage decline",
            "Revenue Volatility Level high",
            "Globalization Level high - increasing",
            "Competition Level high - increasing"
        ],
        "mixed_impact_factors": []
    },
    "swot_analysis": {
        "strengths": [
            "High & Steady Barriers to Entry",
            "High Profit vs. Sector Average",
            "Low Product/Service Concentration"
        ],
        "weaknesses": [
            "High Competition",
            "High Volatility",
            "High Imports",
            "High Customer Class Concentration",
            "High Capital Requirements"
        ],
        "opportunities": [
            "High Revenue Growth (2023-2028)",
            "High Performance Drivers"
        ],
        "threats": [
            "Low Revenue Growth (2005-2023)",
            "Low Revenue Growth (2018-2023)",
            "Low Outlier Growth"
        ]
    },
    "key_trends": [
        "Demand for insulin has consistently grown. But industry revenue has conversely declined over the past five years as major insulin makers start to cut their prices.",
        "The Inflation Reduction Act of 2022 will permanently impact the industry. After years of being overpriced, insulin is now accessible and affordable to a larger share of the population.",
        "The industry is heavily regulated both in terms of quality standards and prices.",
        "Drug patents and exclusivity rights represent the backbone of this industry.",
        "Insulin pens have increased in popularity at the expense of declining syringe sales.",
        "Medicare will represent a larger industry revenue share after the Inflation Reduction Act of 2022 is passed.",
        "Access to talented labor and proximity to foreign markets is crucial.",
        "Pharmaceutical sales align more closely with clinical trials than with availability."
    ],
    "market_segmentation": [
        {
            "segment": "Medicare",
            "segment_description": "Older individuals are more likely to be diabetes-prone. In 2023, Medicare Part D will impose a $35.00 cap on a monthly supply of insulin.",
            "segment_percentage": 48.7
        },
        {
            "segment": "Private insurance",
            "segment_description": "Individuals who don't qualify for both Medicare and Medicaid can purchase their own insurance.",
            "segment_percentage": 22.3
        },
        {
            "segment": "Medicaid",
            "segment_description": "Medicaid is targeting low-income individuals.",
            "segment_percentage": 21.2
        },
        {
            "segment": "Out-of-pocket",
            "segment_description": "Payments that are not reimbursed by the patients' insurers.",
            "segment_percentage": 5.3
        },
        {
            "segment": "Other",
            "segment_description": "Other relevant segments.",
            "segment_percentage": 2.5
        }
    ],
    "products_and_services": [
        {
            "product_or_service": "Fast-Acting Insulin",
            "product_description": "Fast-acting insulin, will take effect within 15 minutes. But its effect only lasts between two and four hours.",
            "product_percentage": 54.6
        },
        {
            "product_or_service": "Long-Acting Insulin",
            "product_description": "Popular brand name long-acting insulin includes Lantus and Basaglar. After Sanofi's Lantus primary patent expired in 2015.",
            "product_percentage": 40.9
        },
        {
            "product_or_service": "Premix Insulin",
            "product_description": "Premix insulin is mixed between fast-acting and long-acting insulin.",
            "product_percentage": 4.5
        }
    ],
    "supply_chain": {
        "tier_1_suppliers": [],
        "tier_2_suppliers": [
            "Inorganic Chemical Manufacturing in the US",
            "Organic Chemical Manufacturing in the US",
            "Industrial Machinery & Equipment Wholesaling in the US"
        ],
        "tier_1_buyers": [
            "Drug, Cosmetic & Toiletry Wholesaling in the US",
            "Laboratory Supply Wholesaling in the US"
        ],
        "tier_2_buyers": [
            "Pharmacies & Drug Stores in the US",
            "Hospitals in the US",
            "Psychiatric Hospitals in the US",
            "Specialty Hospitals in the US",
            "Nursing Care Facilities in the US"
        ]
    },
    "demand_determinants": [
        {
            "determinant_title": "Federal Funding for Medicare and Medicaid",
            "determinant_description": "Medicare represents the largest source of industry revenue."
        },
        {
            "determinant_title": "Number of People with Private Health Insurance",
            "determinant_description": "Individuals ineligible for Medicare and Medicaid can purchase health insurance plans."
        },
        {
            "determinant_title": "Adult Obesity Rate",
            "determinant_description": "Obesity is directly linked to diabetes."
        },
        {
            "determinant_title": "Trade-Weighted Index",
            "determinant_description": "As US dollar strengthens, US-made insulin becomes relatively more expensive."
        }
    ],
    "international_trade": {
        "import_level": "High",
        "import_trend": "Increasing",
        "export_level": "Moderate",
        "export_trend": "Increasing",
        "international_trade_points": [
            {
                "trade_title": "Imports",
                "trade_description": "Most imported insulins come from Germany."
            },
            {
                "trade_title": "Exports",
                "trade_description": "Mexico ranks 7th in the top 10 countries with the highest diabetes rate."
            }
        ]
    },
    "business_locations": [
        {
            "location": "Mid-Atlantic Region",
            "location_description": "New Jersey is a popular hub for insulin manufacturing.",
            "percentage_establishments": 50,
            "percentage_population": 50
        },
        {
            "location": "North Carolina",
            "location_description": "Novo Nordisk's only US insulin manufacturing facility is located in Clayton, North Carolina.",
            "percentage_establishments": 50,
            "percentage_population": 50
        },
        {
            "location": "West",
            "location_description": "California is attractive to insulin manufacturers because of its large labor force market.",
            "percentage_establishments": 50,
            "percentage_population": 50
        }
    ],
    "regulations_and_policies": {
        "regulations_level": "High",
        "regulations_points": [
            {
                "regulation_title": "FDA approval required",
                "regulation_description": "Approval from the FDA of an ANDA is required."
            },
            {
                "regulation_title": "Drug Safety and Accountability Act",
                "regulation_description": "The FDA must establish accurate, interoperable information systems."
            },
            {
                "regulation_title": "The CREATES Act",
                "regulation_description": "The CREATES Act aims to reduce the price of generic drugs."
            },
            {
                "regulation_title": "Prescription Drug User Fee Act",
                "regulation_description": "PDUFA gives the FDA authority to collect user fees from pharmaceutical companies."
            }
        ],
        "regulations_trend": "Increasing"
    },
    "barriers_to_entry": {
        "barriers_level": "High",
        "barriers_trend": "Steady",
        "barriers_points": [
            {
                "barrier_title": "Life Cycle Stage",
                "barrier_description": "Life Cycle Stage: decline"
            },
            {
                "barrier_title": "Revenue Volatility Level",
                "barrier_description": "Revenue Volatility Level: high"
            },
            {
                "barrier_title": "Globalization Level",
                "barrier_description": "Globalization Level: high - increasing"
            },
            {
                "barrier_title": "Competition Level",
                "barrier_description": "Competition Level: high - increasing"
            }
        ],
        "factors_increased_barrier": [],
        "factors_decreased_barrier": [
            "Capital intensity is medium in this industry."
        ]
    },
    "basis_of_competition": {
        "basis_level": "High",
        "basis_trend": "Increasing",
        "basis_points": [
            {
                "basis_title": "Competition from generic drugmakers",
                "basis_description": "Rising competition from generic drugmakers when patents expire."
            },
            {
                "basis_title": "Competition from foreign alternatives",
                "basis_description": "Insulin manufacturers experience competition from foreign alternatives."
            }
        ]
    },
    "market_share_concentration": {
        "concentration_level": "Moderate",
        "concentration_trend": "Increasing",
        "concentration_points": [
            {
                "concentration_title": "Big three control over 90% market share",
                "concentration_description": "The big three control over 90% of the global and US insulin market."
            },
            {
                "concentration_title": "Factors supporting high concentration",
                "concentration_description": "Exclusive patented products and economies of scale."
            }
        ],
        "top_companies": [
            {
                "company_name": "Eli Lilly And Company",
                "company_percentage": 40.1
            },
            {
                "company_name": "Sanofi",
                "company_percentage": 7.7
            },
            {
                "company_name": "Novo Nordisk A",
                "company_percentage": 7.6
            },
            {
                "company_name": "OTHERS",
                "company_percentage": 44.7
            }
        ]
    },
    "cost_structure_breakdown": [
        {
            "cost_type": "Profit",
            "cost_type_percentage": 30
        },
        {
            "cost_type": "Purchases",
            "cost_type_percentage": 50
        },
        {
            "cost_type": "Wages",
            "cost_type_percentage": 15
        },
        {
            "cost_type": "Other",
            "cost_type_percentage": 5
        }
    ],
    "cost_factors": [
        {
            "cost_factor_title": "Research and development costs",
            "cost_factor_description": "Research and development represent one of the highest costs."
        },
        {
            "cost_factor_title": "Purchase costs",
            "cost_factor_description": "Purchases are the Industry's Largest Costs."
        }
    ],
    "capital_intensity": {
        "capital_intensity_level": "Moderate",
        "capital_intensity_points": [
            {
                "capital_intensity_title": "Medical equipment and skilled labor required",
                "capital_intensity_description": "Medical equipment and skilled labor are required to manufacture drugs."
            },
            {
                "capital_intensity_title": "Low innovation limits disruption",
                "capital_intensity_description": "Low levels of innovation limit the threat to incumbent operators."
            }
        ],
        "capital_intensity_trend": "Steady"
    },
    "revenue_volatility": {
        "volatility_level": "High",
        "volatility_points": [
            {
                "volatility_title": "Robust demand insulates from economic woes",
                "volatility_description": "A growing diabetic population shields the industry."
            },
            {
                "volatility_title": "Price cuts cause volatility",
                "volatility_description": "The backlash on overpriced insulin prices induces insulin producers to cut prices."
            }
        ],
        "volatility_trend": "Increasing"
    },
    "technological_change": {
        "technological_change_level": "Moderate",
        "technological_change_points": [
            {
                "technological_change_title": "Fast-acting insulin benefits from lower prices",
                "technological_change_description": "Fast-acting insulin will take effect within 15 minutes."
            },
            {
                "technological_change_title": "Long-acting insulin is second most popular",
                "technological_change_description": "Long-acting insulin takes several hours to take effect."
            }
        ],
        "technological_change_trend": "Increasing"
    },
    "FAQs": [
        {
            "question": "What is the provision about?",
            "answer": "The regulation prevents companies in the Insulin Manufacturing industry from refusing to sell drug samples to other manufacturers."
        },
        {
            "question": "What is the Prescription Drug User Fee Act?",
            "answer": "On September 30, 2022, PDUFA gives the FDA authority to collect user fees."
        },
        {
            "question": "What assistance is provided to the industry?",
            "answer": "Moderate assistance with steady assistance."
        },
        {
            "question": "What is PhRMA?",
            "answer": "PhRMA represents the country's largest biopharmaceutical companies."
        }
    ]
}